Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for AVITA Medical (AVHHL) over the last 7 years, with Q4 2025 value amounting to -$617000.0.

  • AVITA Medical's Gains from Investment Securities fell 19167.9% to -$617000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$322000.0, marking a year-over-year decrease of 12086.84%. This contributed to the annual value of -$2.2 million for FY2025, which is 89890.51% down from last year.
  • As of Q4 2025, AVITA Medical's Gains from Investment Securities stood at -$617000.0, which was down 19167.9% from $5.1 million recorded in Q3 2025.
  • Over the past 5 years, AVITA Medical's Gains from Investment Securities peaked at $5.1 million during Q2 2025, and registered a low of -$617000.0 during Q4 2025.
  • For the 5-year period, AVITA Medical's Gains from Investment Securities averaged around $1.3 million, with its median value being $673000.0 (2024).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 5290000.0% in 2021, then plummeted by 19167.9% in 2025.
  • Over the past 5 years, AVITA Medical's Gains from Investment Securities (Quarter) stood at $1.8 million in 2021, then plummeted by 119.41% to -$341000.0 in 2022, then surged by 281.52% to $619000.0 in 2023, then rose by 8.72% to $673000.0 in 2024, then tumbled by 191.68% to -$617000.0 in 2025.
  • Its Gains from Investment Securities was -$617000.0 in Q4 2025, compared to $5.1 million in Q3 2025 and $5.1 million in Q2 2025.